Belite Bio

Belite Bio is a clinical-stage biopharmaceutical drug development company located in San Diego, targeting incurable age-related metabolic diseases, including macular degeneration, liver disease, and diabetes. Developed from our RBP4 intellectual property portfolio, our lead candidate LBS-008 has entered Phase 3 for Stargardt disease, a hereditary juvenile form of macular degeneration, and is expected to initiate Phase 3 for age-related dry macular degeneration in 2022. LBS-008 has received orphan drug designation in the United States and Europe, as well as rare pediatric disease designation in the United States.